FDA dis­pens­es with in-per­son re­quire­ment for abor­tion pill ac­cess dur­ing the pan­dem­ic

Women seek­ing the abor­tion pill mifepri­s­tone dur­ing the pan­dem­ic will be able to or­der it through the mail and will no longer have to go in­to a clin­ic in per­son, act­ing FDA com­mis­sion­er Janet Wood­cock wrote Mon­day in re­sponse to a se­ries of con­cerns from the Amer­i­can Col­lege of Ob­ste­tri­cians and Gy­ne­col­o­gists and the So­ci­ety for Ma­ter­nal-Fe­tal Med­i­cine.

Mifepri­s­tone is a drug that can end a preg­nan­cy that is less than 10 weeks along, and has cre­at­ed a whirl­wind of po­lit­i­cal and le­gal ques­tions re­lat­ed to this in-per­son re­quire­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER